# SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS

> **NCT07562568** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 160 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- MDS
- Transplantation, Stem Cell
- Conditioning Therapy
- SHR2554
- Azacytidine

## Interventions

- **COMBINATION_PRODUCT:** SHR2554/AZA + Overlapped TBF
- **DRUG:** mBUCY conditioning regimen

## Key facts

- **NCT ID:** NCT07562568
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2030-06
- **Final completion:** 2030-06
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07562568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07562568, "SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07562568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*